Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback